Industry News (HBV)

New Clinical Data Presented on Lamivudine for Hepatitis B Treatment

Published in Hepatitis Weekly, June 8th, 1998

Two clinical studies presented at the Digestive Disease Week (DDW) meeting in New Orleans, Louisiana, add new information about the antiviral drug, lamivudine, in the treatment of patients with chronic hepatitis B.

The studies with lamivudine, an oral antiviral treatment under development by Glaxo Wellcome Inc., showed that the drug offers benefits that can be sustained for as long as two years in patients with chronic hepatitis B.

Currently, established treatments for hepatitis B are designed to boost the immune system. The goal of antiviral treatment with drugs such as lamivudine is to inhibit HBV replication, thus leading to reduced inflammatory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry